The Swedish CDMO Recipharm reaches agreement with LobSor Pharmaceuticals to manufacture LECIGONTM, a proprietary treatment for advanced Parkinson’s disease.
Recipharm and LobSor Pharmaceuticals, an Uppsala-based pharmaceutical company focusing on the development of innovative systems to treat symptoms of advanced Parkinson’s disease (APD), has agreed on a manufacturing agreement for LECIGON. As part of the agreement, Recipharm will have exclusive manufacturing rights for volumes representing first three years of commercial sales. Recipharm will also support development costs against a mark-up on manufacturing prices, up to a certain volume, when LECIGON is produced for commercial sales.
This agreement is a follow-on to an established collaboration between LobSor and Recipharm for the development and the manufacturing of batches for the recently completed clinical trial.
“We are extremely pleased to have developed our collaborative partnership with LobSor Pharmaceuticals and to have signed an agreement for the future commercial manufacturing of LECIGON, especially as this is a new, innovative drug, which we believe provides a clear benefit to patients with advanced Parkinson’s disease,” commented Carl-Johan Spak, EVP Development & Technology, Recipharm.